Janus Kinase Inhibition with Tofacitinib: Changing the Face of Inflammatory Bowel Disease Treatment
Lucine Vuitton, Stéphane Koch and Laurent Peyrin-Biroulet
Affiliation: Inserm U954 and Department of Hepato-Gastroenterology, University Hospital of Nancy-Brabois, Université Henri Poincaré 1 Allée du Morvan, 54511 Vandoeuvre-lès-Nancy, France.
The advent of anti-Tumor Necrosis Factor (TNF) therapy has changed the way of treating inflammatory bowel
disease (IBD). However, primary and secondary failure are relatively frequent with all anti-TNF agents, which are available
only as parenteral agents. Tofacitinib is an oral janus kinase (JAK) inhibitor that inhibits JAK family kinase members,
in particular JAK1 and JAK3, achieving a broad limitation of inflammation by interfering with several cytokine receptors.
It first proved its efficacy as an immunosuppressive regimen after renal transplantation, and was recently approved
by the FDA for rheumatoid arthritis. First data in IBD are promising, especially in ulcerative colitis. Ongoing
clinical trials in both UC and Crohn’s disease (CD) are needed to further explore its efficacy in CD and to better assess its
Keywords: Crohn’s disease, immunosuppression, inflammatory bowel disease, janus kinase, tofacitinib, ulcerative colitis.
Rights & PermissionsPrintExport